New Report Finds Brand Name Drug Companies Increased Prices on New Oncology Treatments by 25 Percent Over Four Years This week, U.S. Representative Katie Porter (D-CA) released a report, “Skyrocketing: How Big Pharma Exploits Launch Prices to Cash in on Cancer,” investigating Big Pharma’s increasingly outrageous launch prices on new cancer drugs — and adding for […]
JAMA Analysis Finds No Correlation Between Cancer Drug Prices and Effectiveness A new study published in the Journal of the American Medical Association (JAMA) Internal Medicine found a lack of correlation between the prices set by Big Pharma on cancer drugs and their effectiveness for patients. “We did not detect a meaningful association between cancer drug prices […]
New Earnings Reports Show Big Pharma Giants Basking in Massive Profits, Beating Wall Street Expectations After Repeatedly Hiking Drug Prices New earnings reports for the third quarter of 2022 continue to demonstrate the pharmaceutical industry is basking in massive profits after repeated price hikes on brand name prescription drugs in their portfolios. Big Pharma giants […]
Areva Pharmaceuticals Price-Gouges Cancer Patients Who Rely on Older Oncology Drug This week, Areva Pharmaceuticals, a U.S.-based drugmaker, brought an older oncology treatment to market used for patients suffering from certain forms of Leukemia. According to reports, the drug, fludarabine, has been in short supply and hospitals and cancer centers have struggled to secure supplies […]
The Problem with Insulin Affordability is the Price, Driven by “Shadow Pricing” Tactics from Brand Name Drug Companies In case you missed it, a new study published in the Annals of Internal Medicine estimated that more than 1.3 million Americans, more than 16 percent of adults prescribed insulin, did not take the drug as prescribed […]
J&J Beats Q3 Earnings Expectations After Dozens of Prescription Drug Price Hikes in 2022 This week, Johnson & Johnson kicked off third-quarter earnings reports for the pharmaceutical industry. The Big Pharma giant once again bested Wall Street analysts’ expectations, driven by strong sales in the company’s pharmaceutical division, after the company raised prices on dozens of […]
HHS Reports Demonstrate Cost of Big Pharma Egregious Pricing Practices and Importance of Solutions to Keep Price Hikes Below the Rate of Inflation In case you missed it, the U.S. Department of Health and Human Services released a pair of reports Friday that demonstrate the cost of Big Pharma’s egregious pricing practices and the importance […]
JAMA Network Open Paper Finds “No Relationship” Between Drug Company’s Prices and Investments in Research and Development On Monday, a new paper published in JAMA Network Open examines Big Pharma’s bogus claims that high prescription drug prices are justified by the amount of research and development (R&D) brand name drug companies invest to bring new products to […]
Biogen Agrees to Settle Case Over Illegally Paying Doctors to Push Brand Name Products to Boost Profits, Undermine Competition On Monday, Big Pharma company Biogen agreed to settle with the U.S. Department of Justice (DOJ) over claims the company paid illegal kickbacks to doctors to prescribe more of the company’s drugs, including brand name multiple sclerosis drugs […]
Novartis Exec Calls Policy to Keep Price Hikes Below Inflation “Manageable” and Suggests Rx Solutions Will Have No Impact on Profits Big Pharma giant Novartis signaled plans at an investor event Thursday to invest more in the U.S. market despite doom and gloom rhetoric from the pharmaceutical industry around the inclusion of drug pricing solutions […]